QP3-RT 30mg
Investigational triple receptor agonist for metabolic research.
The 30 mg vial is the largest QP3-RT format, intended for extended metabolic research programs that need one consistent stock of this investigational triple receptor agonist.
Triple agonism is the newest step in a line of incretin-based peptide design that moved from selective single-receptor analogs to dual incretin-receptor agonists. Adding glucagon-receptor activity introduces a signal that, in hepatic and adipose models, is associated with increased energy expenditure and fatty-acid oxidation, while the incretin receptor activity has been studied for its interaction with glucagon-driven glucose output. Research with QP3-RT explores that balance in preclinical models of energy balance, hepatic lipid handling and glucose handling, and compares the triple profile directly against single and dual agonists.
This vial has a third-party certificate of analysis (batch COA #7965, 99.86% by RP-HPLC, issued by Bioviridian Inc.). Lyophilized and supplied for in-vitro research use only.
Research areas: Incretin agonist evolution, Energy expenditure models, Hepatic lipid metabolism, Glucose homeostasis studies.
Category: Metabolic. Price: $100.00 USD. 99.86% HPLC purity (third-party lab tested, batch COA #7965: https://orderqualitypeptides.com/coa/COA7965.pdf).
All products are sold strictly for in-vitro laboratory research. Not for human or veterinary use. Not drugs or supplements.